Biotech Innovations Company for R&D

About Us

Biotechnology Innovation Company (BIC), established in January 2024 by Dr. Khaled Almosa, a senior strategic management consultant and regional leader in the biotechnology industry, is Saudi Arabia’s first private biotech firm specializing in R&D and clinical trials. BIC provides comprehensive R&D services for vaccines, biologics, and gene therapy, striving to transform advanced science into life-saving health solutions that enhance public health and well-being.

Guided by Saudi Vision 2030 and the national biotechnology strategy, we are actively developing national expertise in vaccine, biologic, and biosimilar R&D, as well as consultation and training services. Through our strategic initiatives, we aim to position Saudi Arabia as a regional biotechnology leader, ready to address emerging health challenges with innovation, agility, and excellence.

Our Services

We drive the discovery and development of cutting-edge vaccines, biologics, and gene therapies to address urgent health challenges, enhancing both local innovation and global health outcomes. By analyzing and improving bioprocess steps, we ensure efficient, scalable manufacturing that supports informed decision-making and optimizes overall production performance. Our targeted training programs in biotechnology and vaccine development aim to build expertise, develop skills, and promote knowledge exchange within the industry. Additionally, we provide expert regulatory support to help navigate both Saudi and international requirements, ensuring compliance and facilitating successful clinical development and product approval.

Saudi National Institute of Health (Saudi NIH)

Biotechnology Innovation Company (BIC) is proud to be the first Saudi biotechnology company to receive approval for a grant from the Saudi National Institutes of Health (Saudi NIH) to conduct Phase 1 clinical trials for Middle East Respiratory Syndrome (MERS). This milestone underscores BIC’s commitment to advancing biotech research and vaccine development in Saudi Arabia.

Saudi National Institutes of Health (Saudi NIH):
The Saudi NIH was established as part of the Kingdom’s Vision 2030 initiative to enhance biomedical research, translational medicine, and clinical trials ⁽¹⁾. It plays a crucial role in supporting health innovation, ensuring high-quality national health research, and promoting preventive healthcare strategies. The institute collaborates with leading global health organizations to address emerging health challenges and improve public health outcomes in Saudi Arabia.

Baylor College of Medicine – A Strategic Partner:
This clinical trial program is conducted in collaboration with Baylor College of Medicine (BCM), USA, a prestigious medical institution based in Houston, Texas ⁽²⁾. BCM is renowned for its cutting-edge research, medical education, and healthcare innovations. It houses four specialized schools, including the National School of Tropical Medicine, which focuses on infectious diseases and vaccine development ⁽²⁾. Baylor’s expertise in virology, immunology, and clinical trials makes it an ideal partner for advancing MERS research and vaccine development.

Middle East Respiratory Syndrome (MERS):
MERS is a viral respiratory illness caused by the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). First identified in Saudi Arabia in 2012, MERS is a zoonotic virus, meaning it can be transmitted from animals (primarily camels) to humans ⁽⁴⁾. The disease has a high mortality rate, with approximately 35% of reported cases resulting in death ⁽⁴⁾. Symptoms include fever, cough, shortness of breath, and in severe cases, pneumonia and kidney failure.

Significance of the Clinical Trial:
- Advancing MERS Research: The Phase 1 clinical trial aims to evaluate the safety and immune response of a potential MERS vaccine.
- Strengthening Saudi Arabia’s Biotech Sector: This initiative aligns with Saudi Vision 2030, fostering local expertise in vaccine development.
- Global Collaboration: Working with Baylor College of Medicine enhances knowledge exchange and research capabilities.
- Public Health Impact: A successful vaccine could prevent future outbreaks and protect high-risk populations.

This collaboration between BIC, Saudi NIH, and Baylor College of Medicine marks a significant step toward strengthening Saudi Arabia’s position in global biotechnology and infectious disease research.

King Abdullah International Medical Research Center (KAIMRC)

Biotechnology Innovation Company (BIC) proudly stands as the first Saudi biotechnology company to receive initial approval for Phase 1 clinical trials at King Abdullah International Medical Research Center (KAIMRC) to study Middle East Respiratory Syndrome (MERS). This milestone reflects BIC’s commitment to advancing biotechnology research and vaccine innovation within Saudi Arabia.

King Abdullah International Medical Research Center (KAIMRC):
As a pioneering medical research institute, KAIMRC plays a fundamental role in shaping the future of biomedical science in Saudi Arabia. Operating under the Ministry of National Guard Health Affairs, KAIMRC is dedicated to developing breakthrough therapies, conducting clinical trials, and fostering translational medicine. The institute collaborates with prestigious global research organizations, focusing on infectious disease control, vaccine development, and public health initiatives to strengthen the national healthcare infrastructure.

Baylor College of Medicine – A Strategic Partner:
This groundbreaking clinical trial program is being conducted in collaboration with Baylor College of Medicine (BCM), USA, a renowned medical and research institution based in Houston, Texas. BCM is distinguished for its cutting-edge contributions to medical sciences, encompassing virology, immunology, and vaccine development. It houses multiple specialized schools, including the National School of Tropical Medicine, which leads advancements in infectious disease prevention and vaccine research. BCM’s expertise makes it an ideal partner in the mission to enhance MERS vaccine development and improve global health security.

This collaboration between BIC, KAIMRC, and Baylor College of Medicine marks a transformative leap in Saudi Arabia’s commitment to biotechnology, vaccine development, and infectious disease research, solidifying its role in global health innovation.